Health Economics›Thyroid cancer medullary›Locally advanced or metastatic disease subsequent lines of therapy

Locally advanced or metastatic disease subsequent lines of therapy

Thyroid cancer medullary · 2 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Cabozantinib monotherapy Variant #01	—	R 90 983	28d	11.2 mo	26.6 mo	13	R 1 182 777 PFS proxy	2
Placebo Partial	—	—	—	11.7 mo	21.1 mo	—	—	3

2 of 2 regimens shown